NeoGenomics (NEO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
21 May, 2026Opening remarks and agenda
The meeting was called to order at 10:00 A.M. EDT on May 21, 2026, and held virtually to increase inclusivity and reach.
The business portion was conducted first, followed by a Q&A session for stockholders.
Board and executive committee updates
Board members and senior management, including the CFO and General Counsel, were introduced.
Representatives from Deloitte & Touche LLP, the independent auditors, were present.
Shareholder proposals
Four proposals were presented: election of nine board members, advisory approval of executive compensation, approval of an amendment to the 2023 Equity Incentive Plan, and ratification of Deloitte & Touche LLP as auditors for 2026.
Partial view of Summaries dataset, powered by Quartr API
Latest events from NeoGenomics
- Double-digit growth, product innovation, and margin expansion drive a strong outlook.NEO
Jefferies Global Healthcare Conference 20264 Jun 2026 - Guidance targets 9–10% growth and margin expansion, fueled by new products and sales force investments.NEO
Leerink Global Healthcare Conference 20265 May 2026 - Q1 2026 revenue up 11% to $187M, adjusted EBITDA up 27%, and net loss narrowed to $17.1M.NEO
Q1 202629 Apr 2026 - Pivotal launches and sales force expansion position the business for accelerated growth and margin gains.NEO
TD Cowen 46th Annual Health Care Conference28 Apr 2026 - Virtual annual meeting to vote on directors, pay, equity plan, and auditor ratification.NEO
Proxy filing6 Apr 2026 - Proxy covers director elections, executive pay, equity plan, auditor ratification, and ESG progress.NEO
Proxy filing6 Apr 2026 - Innovative cancer testing portfolio and community focus fuel double-digit growth and 2026 optimism.NEO
Investor presentation10 Mar 2026 - 2025 revenue up 10% to $727M; NGS and EBITDA growth strong; 2026 outlook positive.NEO
Q4 202517 Feb 2026 - Q2 revenue up 12%, net loss narrows, and Adjusted EBITDA up 630% with raised guidance.NEO
Q2 20242 Feb 2026